<DOC>
	<DOCNO>NCT01231737</DOCNO>
	<brief_summary>Epidemiological study show 20-30 % patient uncomplicated urinary tract infection risk recurrent infection . Urinary tract infection cause marked discomfort patient , negative impact upon quality life , associate high social health cost term specialist appointment , laboratory instrumental test prescription . Although diverse cycle antibiotic therapy prophylaxis propose , doubt persist efficacious pharmacological agent , duration prophylaxis , incidence adverse effect relapse antibiotic therapy suspend . Aims study : 1 . To compare efficacy two prophylactic schedule ( Prulifloxacin v Phosphomycin ) : - reduce number urinary tract infection episode prophylaxis - reduce number urinary tract infection episode prophylaxis - improve patient 's quality life . 2 . To assess : - Tolerability antibiotic prophylaxis - The incidence resistance antibiotic therapy</brief_summary>
	<brief_title>Efficacy Two Prophylactic Schedules ( Prulifloxacin Versus Phosphomycin )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Prulifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<criteria>Female patient Age 18 year old No allergies drug prescribe No counterindications drug therapy Urine culture show responsiveness drug recruitment patient History urinary tract infection least three episode previous year two past six month Lack tolerability prescribe drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Prophylasy</keyword>
	<keyword>recurrent urinary tract infection</keyword>
	<keyword>prulifloxacin</keyword>
	<keyword>phosphomycin</keyword>
</DOC>